EKO / TSX

Noveko International Inc. ("the Company") announces that it is refocusing its strategy for the marketing of its Noveko(TM)masks and respirators in North America. In this regard, the initial 510(k) submission for the Noveko(TM) 3xEZ antibacterial surgical mask to the US Food and Drug Administration ("the FDA") ("the initial FDA submission") has been withdrawn. The prevailing A (H1N1) influenza virus pandemic context and the time and cost imperatives associated with the initial FDA submission process - which took longer and proved more complex than initially expected, moreover being limited to the Noveko(TM) 3xEZ surgical mask which had only an antibacterial claim - led the Company's management to refocus its strategy to prioritize the accelerated marketing of its Noveko(TM) masks and respirators in the United States, outside healthcare institutions, as well as in North America, globally.